Aerie's Rhopressa wins FDA panel votes

An FDA advisory committee voted 9-1 on Oct. 13 that the efficacy of Rhopressa netarsudil 0.02% (AR-13324) from Aerie Pharmaceuticals Inc. (NASDAQ:AERI) shown in clinical trials outweighs the candidate's safety risks. The panel also voted 10-0 that available clinical data support Rhopressa's efficacy to treat elevated intraocular pressure (IOP) in patients with glaucoma and ocular hypertension.

FDA's Dermatologic and Ophthalmologic Drugs Advisory Committee evaluated Rhopressa's NDA, which has a PDUFA date of Feb. 28, 2018...